PHP
ORIC icon

Parkman Healthcare Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Parkman Healthcare Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-203,006
Closed -$1.13M – 97
2025
Q1 		$1.13M Buy
+203,006
New +$1.78M 0.13% 84

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Parkman Healthcare Partners's ORIC Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 203,006 shares — an estimated $1.13M sold.

Parkman Healthcare Partners first reported a position in ORIC in Q1 2025 and held it in 1 quarter. The position peaked at $1.13M in Q1 2025. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Parkman Healthcare Partners reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 203,006 Oric Pharmaceuticals shares in Q2 2025, an estimated $1.13M.
  • Parkman Healthcare Partners first reported a position in Oric Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Parkman Healthcare Partners's Oric Pharmaceuticals position peaked at $1.13M in Q1 2025.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.